Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab + Pegilodecakin |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | predicted - sensitive | Nivolumab + Pegilodecakin | Phase I | Actionable | In a Phase Ib trial (IVY), Pegilodecakin (AM0010) and Keytruda (pembrolizumab) (n=5) or Opdivo (nivolumab) (n=29) combination therapy demonstrated safety and preliminary efficacy in patients with non-small cell lung carcinoma, objective response was observed in 83% (5/6) of patients with CD274 (PD-L1) expression of 50% or higher, and in 67% (2/3) of patients with CD274 (PD-L1) expression less than 50% (PMID: 31563517; NCT02009449). | 31563517 |
PubMed Id | Reference Title | Details |
---|---|---|
(31563517) | Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial. | Full reference... |